2Followers on Owler

EpimAb

Read more
Chengbin Wu's photo - CEO of EpimAb

CEO

Chengbin Wu

CEO Approval Rating

82/100

Founded

2015

Status

PrivateIndependent Company

Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
25-100
Agree?
Funding
$219M
Industry

Update Industry
Sector

Update Industry

EpimAb Competitors and Alternatives

1
3
5
7
9
2
4
6
8
10
See more competitor data

EpimAb News

EpimAb Blogs

EpimAb Press Releases

EpimAb Headquarters

702 Zhongke Road

Shanghai, Shanxi Province201204

86-21-61951000

Driving Directions »

EpimAb Summary

ABOUT

Overview

Epimab is a China-based biopharmaceutical company that develops novel bi-specific antibody therapeutics for the treatment of cancer, inflammatory and autoimmune diseases. EpimAb was founded in 2015. EpimAb's headquarters is located in Shanghai, Shanxi...

CEO

EpimAb's CEO, Chengbin Wu, currently has an approval rating of 82%. EpimAb's primary competitors are Aridis, Fine Test & DimAb.

Website

epimab.com

Acquisitions

There have been no acquisitions found related to EpimAb

Investments

Recent investment data cannot be found related to EpimAb

Frequently Asked Questions about EpimAb

  1. When was EpimAb founded?

    EpimAb was founded in 2015
  2. Who is EpimAb's CEO?

    EpimAb's CEO is Chengbin Wu
  3. How much revenue does EpimAb generate?

    EpimAb generates $9.3M in revenue
  4. How much funding does EpimAb have?

    EpimAb has historically raised $219M in funding
  1. Where is EpimAb's headquarters?

    EpimAb's headquarters is in Shanghai Shanxi Province, CN
  2. How many employees does EpimAb have?

    EpimAb has 46 employees
  3. Who are EpimAb's competitors?

    EpimAb's top competitors are Aridis, Fine Test, DimAb

Trending Companies